DelveInsight Business Research LLP

DelveInsight’s “HR-positive/HER2-negative Breast Cancer Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the HR-positive/HER2-negative Breast Cancer pipeline landscapes. It comprises HR-positive/HER2-negative Breast Cancer pipeline drug profiles, including clinical and non-clinical stage products. It also includes the HR-positive/HER2-negative Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive HR-positive/HER2-negative Breast Cancer pipeline products.   

Some of the key takeaways of the HR-positive/HER2-negative Breast Cancer Pipeline Report  

• Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Jiangsu HengRui Medicine, Radius Pharmaceuticals, Immunomedics, Roche, Syndax Pharmaceuticals, Merck Sharp and Dohme, Merck Sharp and Dohme Corp./Eisai, Bayer, etc., are developing therapies for the treatment of HR-positive/HER2-negative Breast Cancer.

• Emerging therapies such as SHR6390, Elacestrant (RAD1901), Sacituzumab govitecan, Ipatasertib and Venclexta, Entinostat, Pembrolizumab, Eribulin Mesylate, Radium-223 dichloride, are expected to have a significant impact on the  HR-positive/HER2-negative Breast Cancer market in the coming years.

• The postmenopausal breast cancer market size within the 7MM was found to be USD 6,315.1 million in 2018.

• The HR-positive/HER2-negative Breast Cancer market size shall increase during the forecast period 2021–2030.

• Among the 7MM, the US accounts for 80.51% USD of the HR-positive/HER2-negative Breast Cancer market size in 2018. 

Get an overview of pipeline landscape @HR-positive/HER2-negative Breast Cancer Clinical Trials Analysis  

HR-positive/HER2-negative breast cancer is the commonest carcinoma and also accounts for a better percentage of all breast cancers. HR-positive cancer is typically treated with hormone therapies or a combination of hormone therapies with targeted therapy to assist stop tumor growth. 

HR-positive/HER2-negative Breast Cancer Emerging Drugs

• SHR6390 by Jiangsu HengRui Medicine

• Elacestrant (RAD1901) by Radius Pharmaceuticals

• Sacituzumab govitecan by Immunomedics

• Ipatasertib and Venclexta by Roche

• Entinostat by Syndax Pharmaceuticals

• Pembrolizumab by Merck Sharp and Dohme 

• Eribulin Mesylate by Merck Sharp and Dohme Corp./Eisai   

• Radium-223 dichloride by Bayer

• And others.

Scope of HR-positive/HER2-negative Breast Cancer Pipeline Drug Insight

• Coverage: Global 

• Major Players: Jiangsu HengRui Medicine, Radius Pharmaceuticals, Immunomedics, Roche, Syndax Pharmaceuticals, Merck Sharp and Dohme, Merck Sharp and Dohme Corp./Eisai, Bayer, and others.

• Pipeline Therapies: SHR6390, Elacestrant (RAD1901), Sacituzumab govitecan, Ipatasertib and Venclexta, Entinostat, Pembrolizumab, Eribulin Mesylate, Radium-223 dichloride, and others.

Table of Contents

Get a customized pipeline report @HR-positive/HER2-negative Breast Cancer Drugs Pipeline Report

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/